NCT00819624

Brief Summary

The study has two goals. The first goal of the study is to compare two methods of administering questions about pain and sleep interference. The two methods being compared are a telephone based system and an electronic hand held diary. The second goal of the study is to evaluate a daily diary to evaluate fatigue symptoms in patients with fibromyalgia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
185

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2009

Shorter than P25 for not_applicable

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

January 7, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 9, 2009

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2009

Completed
Last Updated

February 15, 2010

Status Verified

February 1, 2010

Enrollment Period

2 months

First QC Date

January 7, 2009

Last Update Submit

February 12, 2010

Conditions

Keywords

fibromyalgia methodology pain sleep fatigue

Outcome Measures

Primary Outcomes (4)

  • Daily questions about pain asked using a telephone based system and a hand held diary

    4 weeks

  • Daily questions about sleep asked using a telephone based system and a hand held diary

    4 weeks

  • Daily questions about fatigue asked hand held electronic diary

    2 weeks

  • Questionaires about pain, fatigue, function, quality of life, patients impression of change and diary ease of use

    4 weeks

Secondary Outcomes (1)

  • Questionaires about sleep, mood and fibromyalgia severity

    4 weeks

Study Arms (2)

Interactive Voice Response System

OTHER
Other: Interactive Voice Response System (IVRS)

Personal Digital Assisstant

OTHER
Other: Personal Digital Assisstant (PDA)

Interventions

Telephone based system

Interactive Voice Response System

Electronic Hand Held diary

Personal Digital Assisstant

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Fibromyalgia using ACR diagnosis

You may not qualify if:

  • Other confounding disease including other inflammatory disease, pain and depression

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Pfizer Investigational Site

Roseville, California, 95661, United States

Location

Pfizer Investigational Site

Baton Rouge, Louisiana, 70809, United States

Location

Pfizer Investigational Site

North Dartmouth, Massachusetts, 02747, United States

Location

Pfizer Investigational Site

Jefferson City, Missouri, 65109, United States

Location

Pfizer Investigational Site

St Louis, Missouri, 63141, United States

Location

Pfizer Investigational Site

Omaha, Nebraska, 68114, United States

Location

Pfizer Investigational Site

Johnson City, New York, 13790, United States

Location

Pfizer Investigational Site

Winston-Salem, North Carolina, 27103, United States

Location

Pfizer Investigational Site

Cincinnati, Ohio, 45219, United States

Location

Pfizer Investigational Site

Johnson City, Tennessee, 37601, United States

Location

Pfizer Investigational Site

New Tazewell, Tennessee, 37825, United States

Location

Pfizer Investigational Site

Lake Jackson, Texas, 77566, United States

Location

Pfizer Investigational Site

Charlottesville, Virginia, 22911, United States

Location

Pfizer Investigational Site

Richmond, Virginia, 23294, United States

Location

Pfizer Investigational Site

Spokane, Washington, 99216, United States

Location

Related Links

MeSH Terms

Conditions

Fibromyalgia

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

January 7, 2009

First Posted

January 9, 2009

Study Start

January 1, 2009

Primary Completion

March 1, 2009

Study Completion

March 1, 2009

Last Updated

February 15, 2010

Record last verified: 2010-02

Locations